Recherche Images Maps Play YouTube Actualités Gmail Drive Plus »
Connexion
Les utilisateurs de lecteurs d'écran peuvent cliquer sur ce lien pour activer le mode d'accessibilité. Celui-ci propose les mêmes fonctionnalités principales, mais il est optimisé pour votre lecteur d'écran.

Brevets

  1. Recherche avancée dans les brevets
Numéro de publicationUS20060178738 A1
Type de publicationDemande
Numéro de demandeUS 11/398,826
Date de publication10 août 2006
Date de dépôt5 avr. 2006
Date de priorité24 avr. 1997
Autre référence de publicationDE69801459D1, DE69801459T2, EP0873732A1, EP0873732B1, US6605114, US6776792, US7077860, US20040236417
Numéro de publication11398826, 398826, US 2006/0178738 A1, US 2006/178738 A1, US 20060178738 A1, US 20060178738A1, US 2006178738 A1, US 2006178738A1, US-A1-20060178738, US-A1-2006178738, US2006/0178738A1, US2006/178738A1, US20060178738 A1, US20060178738A1, US2006178738 A1, US2006178738A1
InventeursJohn Yan, Randy Chan
Cessionnaire d'origineYan John Y, Randy Chan
Exporter la citationBiBTeX, EndNote, RefMan
Liens externes: USPTO, Cession USPTO, Espacenet
Coated endovascular stent
US 20060178738 A1
Résumé
An implantable stent is coated with a material that attracts heparin and with which heparin forms a bond. The stent is exposed to a heparin containing solution just prior to implantation or is first implanted and then exposed to heparinized blood. As heparin becomes detached from the stent, the implantation site is exposed to heparin to restore an effective level and thereby prevent thrombosis.
Images(2)
Previous page
Next page
Revendications(22)
1. A method of making a medical device comprising:
providing an implantable support structure;
depositing a coating on the support structure, the coating including functional groups that attract heparin;
implanting the support structure in the patient's vasculature; and
exposing the implanted support structure to heparinized blood such that heparin attaches to the coating.
2. The method of claim 1, wherein heparin attaches to the coating via ionic bonds.
3. The method of claim 1, wherein exposing the implantable support structure to heparinized blood comprises delivering heparin from a catheter to the patient.
4. The method of claim 1, wherein the coating is deposited on the entire support structure.
5. The method of claim 1, wherein the support structure is configured such that upon implantation in a blood vessel, such support structure has surfaces that face the vessel walls and surfaces that face the blood flow and wherein the coating is exclusively deposited on the surfaces that face the blood flow.
6. The method of claim 1, wherein the support structure is configured such that upon implantation in a blood vessel, such support structure has surfaces that face the vessel walls, surfaces that face the blood flow and an upstream edge and a downstream edge and wherein the coating is exclusively deposited on at least one of the edges.
7. The method of claim 1, wherein the coating is deposited on the support structure by dipping, spraying or molding.
8. The method of claim 1, wherein the coating is deposited on the support structure by plasma deposition.
9. The method of claim 1, wherein the coating is deposited by first depositing a base layer, selected for its ability to adhere to the support structure and then depositing thereon a top layer selected for its ability to bond to the base layer and avail the functional groups for attachment to the heparin.
10. The method of claim 1, further comprising repeatedly exposing the implanted support structure to heparinized blood in order to maintain a heparin level on the stent.
11. The method of claim 1, wherein the functional groups are selected from a group consisting of amine and carboxyl groups.
12. A method of making a medical device, comprising:
providing an implantable support structure;
depositing a coating on the support structure, the coating including functional groups that attract heparin, bond with heparin, or a combination thereof,
when the coating is exposed to heparin;
sterilizing and storing the support structure having the coating deposited thereon;
exposing the coated support structure to a heparin-containing solution; and
implanting the structure in the patient's vasculature.
13. The method of claim 12, wherein the coating is deposited on the entire support structure.
14. The method of claim 12, wherein the support structure is configured such that upon implantation in a blood vessel, such support structure has surfaces that face the vessel walls and surfaces that face the blood flow and wherein the coating is exclusively deposited on the surfaces that face the blood flow.
15. The method of claim 12, wherein the support structure is configured such that upon implantation in a blood vessel, such support structure has surfaces that face the vessel walls, surfaces that face the blood flow and an upstream edge and a downstream edge and wherein the coating is exclusively deposited on at least one of the edges.
16. The method of claim 12, wherein the coating is deposited on the support structure by dipping, spraying or molding.
17. The method of claim 12, wherein the coating is deposited on the support structure by plasma deposition.
18. The method of claim 12, wherein the coating is deposited by first depositing a base layer, selected for its ability to adhere to the support structure and then depositing thereon a top layer selected for its ability to bond to the base layer and avail the functional groups for attachment to the heparin.
19. The method of claim 12, further comprising exposing the implanted support structure to heparinized blood in order to maintain a heparin level on the support structure.
20. The method of claim 12, wherein the functional groups are selected from a group consisting of amine and carboxyl groups.
21. The method of claim 12, wherein the bonding of the coating with heparin comprises a combination of ionic bonding and covalent bonding.
22. The method of claim 12, wherein the support structure comprises a stent.
Description
    CROSS REFERENCE
  • [0001]
    This is a divisional application of application Ser. No. 10/877,527 filed on Jun. 24, 2004, which is a divisional application of application Ser. No. 08/847,763 filed on Apr. 24, 1997, now U.S. Pat. No. 6,776,792.
  • BACKGROUND OF THE INVENTION
  • [0002]
    The present invention relates to endovascular stents and more particularly pertains to coatings that are applied to stents in order to reduce thrombogenicity.
  • [0003]
    Stents are implanted within blood vessels in an effort to maintain their patency by preventing collapse of the lumen and/or by impeding restenosis. Unfortunately, the presence of a foreign object within the blood flow may have a thrombogenic effect. It has therefore been found to be desirable to use various anti-coagulant drugs in an effort to reduce the likelihood of the development of restenosis and provide an antithrombogenic effect.
  • [0004]
    A drug that has been found to be particularly effective for such purpose is heparin. By maintaining an effective concentration of the drug in and about the implantation site until the stent is encapsulated by tissue, the risk of thrombogenesis is substantially mitigated. To that end, various approaches have been employed in the administration of heparin.
  • [0005]
    While the systemic administration of heparin can cause the implantation site to be subjected to an effective level of heparin, such level of heparin would necessarily also be present throughout the rest of the body which can lead to undesirable side effects such as bleeding. It has therefore been recognized that a regimen wherein the heparin is substantially constrained to the implantation site is far more desirable. An approach that has been devised to achieve such end requires the coating or impregnation of the stent itself with heparin. The heparin is thereby concentrated where it is most needed while its presence, and consequently its effect, throughout the rest of the body is minimized.
  • [0006]
    Disadvantages associated with heretofore known heparinized stents include, the limited shelf life of such devices, the fact the heparin is degraded when the stent is sterilized either by heat or by exposure to ethylene dioxide, the inability of the physician to alter the dosage that the patient is subjected to and the inability to replenish any heparin that may be lost while the device is deployed. Additionally, the cost of heretofore known heparinized stent devices has been very high as it necessarily includes the costs associated with the stringent regulatory requirements attendant a drug containing device.
  • [0007]
    The prior art has been unable to overcome these disadvantages and shortcomings and a new approach is needed to safely, effectively, and economically deliver heparin to an implantation site.
  • SUMMARY OF THE INVENTION
  • [0008]
    The present invention provides for the coating of an implantable endovascular device to facilitate the subsequent loading of heparin onto its surface. Such loading can be achieved in vitro just prior to implantation or preferably, in vivo after the device is in place. As a result, the device has a considerably longer shelf-life than heparin-containing devices, the need for special handling and sterilization procedures associated with heparin-containing devices is obviated, and the dosage of heparin can be readily tailored to an individual patient's needs including any adjustment that may be required after the device has been deployed. An additional advantage provided by such a device is that it is not subject to the stringent regulatory requirements associated with drug-containing devices.
  • [0009]
    More particularly, the present invention provides for the coating of stent surfaces with a material or combination of materials that are selected for their ability to adhere to the stent surface, to attract heparin and to form preferably an ionic bond therewith. The heparin is attracted by and attaches to functional groups incorporated in the coating which may include primary, secondary, and/or tertiary amines or other functionalities such as carboxyl groups.
  • [0010]
    The heparin-attracting coating may be applied so as to encapsulate the entire stent or alternatively, to cover only selected surfaces thereof. By limiting coverage to only the inner surface of the stent, i.e., the surface that is directly exposed to blood flow, a much higher level of heparin can be loaded onto the stent than would be safe if such level were in direct contact with the vessel wall. A toxic effect on the vessel wall is thereby avoided while the blood is exposed to a more effective concentration of heparin. Alternatively, it may be deemed sufficient to coat only the ends of the stent, i.e., where disturbance of flow is greatest and where thromboses are most likely to occur.
  • [0011]
    The coating may be applied by different processes such as by dipping, spraying or molding. The preferred method is by plasma deposition wherein a base layer, selected for its ability to adhere to the stent surface, is first deposited on the stent followed by the deposition of a top layer thereon that is selected for its ability to bond to the base layer and to avail the appropriate functional groups for bonding to the heparin.
  • [0012]
    These and other features and advantages of the present invention will become apparent from the following detailed description which, taken in conjunction with the accompanying drawings, illustrates by way of example the principles of the invention.
  • BRIEF DESCRIPTION OF THE DRAWINGS
  • [0013]
    FIG. 1 is a perspective view of an implantable stent.
  • [0014]
    FIG. 2 is a greatly enlarged, schematic, cross-sectional view of a portion of the stent of the present invention.
  • DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS
  • [0015]
    A wide variety of different stent configurations have been devised to address various issues inherent in their use and function. Additionally, various materials have been employed in their construction including metals and polymers. Both the degree of turbulence caused by a particular stent configuration when subjected to blood flow as well as the material from which it is constructed affects the degree of thrombogenicity associated with a particular stent device. The present invention provides a coating for such stents to which heparin becomes attached and thus serves to reduce or eliminate thrombosis formation. Moreover, the stent's coating allows the heparin to be loaded thereon immediately before the implantation procedure or after the stent is in place.
  • [0016]
    Critical requirements for the coating of the present invention include that it adheres to the stent surface and that it has functional groups that attract heparin and to which heparin bonds. Functional groups that are known to have the requisite affinity for heparin include primary, secondary, and tertiary amines wherein primary amines are preferred due to their enhanced affinity. Alternatively, carboxyl groups may be used. The functional groups must include positively charged entities that serve to attract the negatively charged entities associated with the heparin. Such attraction facilitates the formation of an ionic bond.
  • [0017]
    The coating can be applied by different processes such as by dipping, spraying, molding or by plasma deposition. Plasma deposition is preferred and first requires the deposition of a base layer or primer that prepares the surface of the stent to receive the functionality group containing substance. In the preferred embodiment, a metallic stent is first plasma deposited with methane gas leaving a film on the surface of the stent wherein the methane molecules are oriented with the carbon against the stent and the hydrogen exposed. A top layer that includes the desired functionalities is then deposited on the base layer. Such second layer may be formed by the plasma deposition of ammonia gas to leave the primary amine functional groups extending from the stent surface. Other chemicals such as alkylamine, nitrile compounds or amine containing monomers can also be used to plasma deposit amine functionalities on the surface. In the event a mixture of primary, secondary, and tertiary amines is deposited by such methods it is preferred that the primary amine constitutes a greater percentage of the mixture due to its greater affinity for heparin. Alternatively, the deposition of carboxyl functional groups can be achieved by the plasma deposition of monomers like methyl methacrylate or acrylic acid.
  • [0018]
    The resulting coating thickness should be 0.001 inch or less while a thickness less than 1 micron is preferred. Although it may be desirable to have a uniform concentration of functional groups extending from the surface, it is not critical to the function of the coating. On the other hand, a concentration of at least 54 picamoles/stent must be achieved in order to ensure that heparin becomes attached at an effective level.
  • [0019]
    The coating may be applied to the entire stent or just to selected surfaces thereon. FIG. 1 generally illustrates a stent 12 in its deployed state and serves to identify the vessel wall-facing surface 14, the blood flow-facing surface 16, its upstream edge 18, and its downstream edge 20. By coating only the surfaces facing the blood flow, a concentration of heparin can be loaded thereon that would be toxic to the vessel wall tissue if it were to be present on the surfaces in direct contact with the vessel wall. Alternatively, it may be sufficient to exclusively coat the upstream and/or downstream edges of the stent for a particular stent configuration implanted in a particular patient as thrombosis is most likely to occur at such interfaces due to turbulence induced by their presence in the blood flow.
  • [0020]
    After the coating process is completed, the coated stent is cleaned and sterilized and appropriately packaged for long-term storage. Due to the absence of any degradable drugs or substances on the stent, a fairly extended shelf-life can be expected.
  • [0021]
    The stent of the present invention can be used in two different ways. A first use calls for the stent to be implanted in the form in which it had been stored, without having heparin loaded thereon. Once in place, it is contacted with heparinized blood, either by an injection of heparin via a catheter extended to a position just upstream of the implantation site or by IV. As the heparin macromolecules 22 pass by the functional groups 24 in the coating 26, the heparin is attracted thereto and becomes attached (FIG. 2). Heparin that does not attach, quickly becomes diluted downstream of the implantation site to levels that do not adversely affect the patient. Subsequent heparin flow past the implantation site can cause more and more heparin molecules to be pulled from the blood flow until the stent coating is saturated. Once attached, heparin can inhibit coagulation by binding with anti-thrombin III and/or other factors of the coagulation cascade. Should a heparin molecule become detached, it is replaced by other heparin molecules still present in the blood flow. Alternatively, an additional dosage of heparin can be administered.
  • [0022]
    Alternatively, the physician may pre-treat the stent prior to implantation by flushing it with, for example, a heparinized saline solution. In this way, the physician can easily and precisely adjust the heparin level by controlling the concentration of the heparin in the saline solution and/or controlling the exposure time thereto. Once implanted, the heparin level can be increased or replenished by introducing heparin into the blood flow upstream of the implantation site as was described above. The heparin level is maintained on the stent until the natural healing processes cause the stent surfaces to be completely covered by tissue at which point thrombogenicity ceases to be of concern.
  • [0023]
    While a particular form of the invention has been illustrated and described, it will also be apparent to those skilled in the art that various modifications can be made without departing from the spirit and scope of the invention. Accordingly, it is not intended that the invention be limited except by the appended claims.
Citations de brevets
Brevet cité Date de dépôt Date de publication Déposant Titre
US2701559 *2 août 19518 févr. 1955Cooper William AApparatus for exfoliating and collecting diagnostic material from inner walls of hollow viscera
US4075045 *9 févr. 197621 févr. 1978International Business Machines CorporationMethod for fabricating FET one-device memory cells with two layers of polycrystalline silicon and fabrication of integrated circuits containing arrays of the memory cells charge storage capacitors utilizing five basic pattern deliberating steps
US4132357 *23 juin 19762 janv. 1979Inmont CorporationApparatus and method for spray application of solvent-thinned coating compositions
US4633873 *26 avr. 19846 janv. 1987American Cyanamid CompanySurgical repair mesh
US4638805 *30 juil. 198527 janv. 1987Advanced Cardiovascular Systems, Inc.Self-venting balloon dilatation catheter and method
US4718907 *20 juin 198512 janv. 1988Atrium Medical CorporationVascular prosthesis having fluorinated coating with varying F/C ratio
US4722335 *20 oct. 19862 févr. 1988Vilasi Joseph AExpandable endotracheal tube
US4723549 *18 sept. 19869 févr. 1988Wholey Mark HMethod and apparatus for dilating blood vessels
US4800882 *13 mars 198731 janv. 1989Cook IncorporatedEndovascular stent and delivery system
US4902289 *9 août 198820 févr. 1990Massachusetts Institute Of TechnologyMultilayer bioreplaceable blood vessel prosthesis
US4988356 *25 avr. 198829 janv. 1991C. R. Bard, Inc.Catheter and guidewire exchange system
US4994033 *25 mai 198919 févr. 1991Schneider (Usa) Inc.Intravascular drug delivery dilatation catheter
US4994298 *18 avr. 199019 févr. 1991Biogold Inc.Method of making a biocompatible prosthesis
US4994560 *24 juin 198719 févr. 1991The Dow Chemical CompanyFunctionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies
US5078720 *2 mai 19907 janv. 1992American Medical Systems, Inc.Stent placement instrument and method
US5081394 *31 août 198814 janv. 1992Hitachi, Ltd.Black matrix color picture tube
US5084065 *10 juil. 198928 janv. 1992Corvita CorporationReinforced graft assembly
US5085629 *27 sept. 19894 févr. 1992Medical Engineering CorporationBiodegradable stent
US5087244 *27 sept. 199011 févr. 1992C. R. Bard, Inc.Catheter and method for locally applying medication to the wall of a blood vessel or other body lumen
US5087394 *9 nov. 198911 févr. 1992Scimed Life Systems, Inc.Method for forming an inflatable balloon for use in a catheter
US5176638 *22 mai 19915 janv. 1993Don Michael T AnthonyRegional perfusion catheter with improved drug delivery control
US5188734 *21 févr. 199223 févr. 1993Memtec America CorporationUltraporous and microporous integral membranes
US5275012 *7 janv. 19934 janv. 1994Ford Motor CompanyClimate control system for electric vehicle
US5276015 *18 mars 19924 janv. 1994Washington UniversityMethod of inhibiting microvascular thrombosis
US5278200 *30 oct. 199211 janv. 1994Medtronic, Inc.Thromboresistant material and articles
US5279594 *23 mai 199018 janv. 1994Jackson Richard RIntubation devices with local anesthetic effect for medical use
US5282823 *19 mars 19921 févr. 1994Medtronic, Inc.Intravascular radially expandable stent
US5282860 *8 oct. 19921 févr. 1994Olympus Optical Co., Ltd.Stent tube for medical use
US5286254 *28 août 199215 févr. 1994Cortrak Medical, Inc.Drug delivery apparatus and method
US5380299 *30 août 199310 janv. 1995Med Institute, Inc.Thrombolytic treated intravascular medical device
US5383925 *14 sept. 199224 janv. 1995Meadox Medicals, Inc.Three-dimensional braided soft tissue prosthesis
US5383927 *15 avr. 199324 janv. 1995Intervascular Inc.Non-thromogenic vascular prosthesis
US5385580 *21 sept. 199231 janv. 1995Meadox Medicals, Inc.Self-supporting woven vascular graft
US5387450 *27 févr. 19927 févr. 1995Landec CorporationTemperature-activated adhesive assemblies
US5389106 *29 oct. 199314 févr. 1995Numed, Inc.Impermeable expandable intravascular stent
US5485496 *22 sept. 199416 janv. 1996Cornell Research Foundation, Inc.Gamma irradiation sterilizing of biomaterial medical devices or products, with improved degradation and mechanical properties
US5591199 *7 juin 19957 janv. 1997Porter; Christopher H.Curable fiber composite stent and delivery system
US5591224 *15 sept. 19947 janv. 1997Medtronic, Inc.Bioelastomeric stent
US5591227 *27 avr. 19957 janv. 1997Medtronic, Inc.Drug eluting stent
US5591607 *6 juin 19957 janv. 1997Lynx Therapeutics, Inc.Oligonucleotide N3→P5' phosphoramidates: triplex DNA formation
US5593403 *14 sept. 199414 janv. 1997Scimed Life Systems Inc.Method for modifying a stent in an implanted site
US5593434 *7 juin 199514 janv. 1997Advanced Cardiovascular Systems, Inc.Stent capable of attachment within a body lumen
US5595722 *7 juin 199521 janv. 1997Neorx CorporationMethod for identifying an agent which increases TGF-beta levels
US5599301 *22 nov. 19934 févr. 1997Advanced Cardiovascular Systems, Inc.Motor control system for an automatic catheter inflation system
US5599307 *29 sept. 19954 févr. 1997Loyola University Of ChicagoCatheter and method for the prevention and/or treatment of stenotic processes of vessels and cavities
US5599352 *15 sept. 19944 févr. 1997Medtronic, Inc.Method of making a drug eluting stent
US5599922 *18 mars 19944 févr. 1997Lynx Therapeutics, Inc.Oligonucleotide N3'-P5' phosphoramidates: hybridization and nuclease resistance properties
US5605696 *30 mars 199525 févr. 1997Advanced Cardiovascular Systems, Inc.Drug loaded polymeric material and method of manufacture
US5707385 *16 nov. 199413 janv. 1998Advanced Cardiovascular Systems, Inc.Drug loaded elastic membrane and method for delivery
US5711763 *30 juin 199527 janv. 1998Tdk CorporationComposite biological implant of a ceramic material in a metal substrate
US5711812 *6 juin 199527 janv. 1998Varian Associates, Inc.Apparatus for obtaining dose uniformity in plasma doping (PLAD) ion implantation processes
US5711958 *11 juil. 199627 janv. 1998Life Medical Sciences, Inc.Methods for reducing or eliminating post-surgical adhesion formation
US5713949 *6 août 19963 févr. 1998Jayaraman; SwaminathanMicroporous covered stents and method of coating
US5716981 *7 juin 199510 févr. 1998Angiogenesis Technologies, Inc.Anti-angiogenic compositions and methods of use
US5718726 *11 sept. 199617 févr. 1998Biotronik Mess- und Therapiegerate GmbH & CoMethod of attaching heparin to, and immobilizing it on, inorganic substrate surfaces of cardiovascular implants
US5720726 *20 sept. 199624 févr. 1998Medtronic, Inc.Balloon catheter having retention enhancements on the balloon
US5721131 *28 avr. 199424 févr. 1998United States Of America As Represented By The Secretary Of The NavySurface modification of polymers with self-assembled monolayers that promote adhesion, outgrowth and differentiation of biological cells
US5855598 *27 mai 19975 janv. 1999Corvita CorporationExpandable supportive branched endoluminal grafts
US5855612 *10 mai 19965 janv. 1999Ohta Inc.Biocompatible titanium implant
US5855618 *13 sept. 19965 janv. 1999Meadox Medicals, Inc.Polyurethanes grafted with polyethylene oxide chains containing covalently bonded heparin
US5857998 *2 juin 199712 janv. 1999Boston Scientific CorporationStent and therapeutic delivery system
US5858556 *21 janv. 199712 janv. 1999Uti CorporationMultilayer composite tubular structure and method of making
US5858746 *25 janv. 199512 janv. 1999Board Of Regents, The University Of Texas SystemGels for encapsulation of biological materials
US5858990 *4 mars 199712 janv. 1999St. Elizabeth's Medical CenterFas ligand compositions for treatment of proliferative disorders
US5860954 *29 sept. 199719 janv. 1999Boston Scientific CorporationMultiple hole drug delivery balloon
US5865723 *29 déc. 19952 févr. 1999Ramus Medical TechnologiesMethod and apparatus for forming vascular prostheses
US5865814 *6 août 19972 févr. 1999Medtronic, Inc.Blood contacting medical device and method
US5866113 *7 mars 19972 févr. 1999Medtronic, Inc.Medical device with biomolecule-coated surface graft matrix
US6010445 *12 nov. 19974 janv. 2000Implant Sciences CorporationRadioactive medical device and process
US6010530 *18 févr. 19984 janv. 2000Boston Scientific Technology, Inc.Self-expanding endoluminal prosthesis
US6010573 *1 juil. 19984 janv. 2000Virginia Commonwealth UniversityApparatus and method for endothelial cell seeding/transfection of intravascular stents
US6011125 *25 sept. 19984 janv. 2000General Electric CompanyAmide modified polyesters
US6013099 *29 avr. 199811 janv. 2000Medtronic, Inc.Medical device for delivering a water-insoluble therapeutic salt or substance
US6015541 *3 nov. 199718 janv. 2000Micro Therapeutics, Inc.Radioactive embolizing compositions
US6168617 *14 juin 19992 janv. 2001Scimed Life Systems, Inc.Stent delivery system
US6168619 *16 oct. 19982 janv. 2001Quanam Medical CorporationIntravascular stent having a coaxial polymer member and end sleeves
US6169170 *3 sept. 19972 janv. 2001Lynx Therapeutics, Inc.Oligonucleotide N3′→N5′Phosphoramidate Duplexes
US6171609 *23 oct. 19959 janv. 2001Neorx CorporationTherapeutic inhibitor of vascular smooth muscle cells
US6172167 *27 juin 19979 janv. 2001Universiteit TwenteCopoly(ester-amides) and copoly(ester-urethanes)
US6174316 *30 juin 199916 janv. 2001Medtronic, Inc.Stent delivery system
US6174330 *1 août 199716 janv. 2001Schneider (Usa) IncBioabsorbable marker having radiopaque constituents
US6177523 *14 juil. 199923 janv. 2001Cardiotech International, Inc.Functionalized polyurethanes
US6180632 *24 nov. 199830 janv. 2001Aventis Pharmaceuticals Products Inc.Quinoline and quinoxaline compounds which inhibit platelet-derived growth factor and/or p56lck tyrosine kinases
US6335029 *3 déc. 19981 janv. 2002Scimed Life Systems, Inc.Polymeric coatings for controlled delivery of active agents
US6503538 *30 août 20007 janv. 2003Cornell Research Foundation, Inc.Elastomeric functional biodegradable copolyester amides and copolyester urethanes
US6503556 *28 déc. 20007 janv. 2003Advanced Cardiovascular Systems, Inc.Methods of forming a coating for a prosthesis
US6503954 *21 juil. 20007 janv. 2003Advanced Cardiovascular Systems, Inc.Biocompatible carrier containing actinomycin D and a method of forming the same
US6504307 *30 nov. 20007 janv. 2003Advanced Cardiovascular Systems, Inc.Application of variable bias voltage on a cylindrical grid enclosing a target
US6506437 *17 oct. 200014 janv. 2003Advanced Cardiovascular Systems, Inc.Methods of coating an implantable device having depots formed in a surface thereof
US6510722 *10 mai 200028 janv. 2003Advanced Cardiovascular Systems, Inc.Stent crimping tool for producing a grooved crimp
US6511748 *6 janv. 199928 janv. 2003Aderans Research Institute, Inc.Bioabsorbable fibers and reinforced composites produced therefrom
US6673154 *28 juin 20016 janv. 2004Advanced Cardiovascular Systems, Inc.Stent mounting device to coat a stent
US6673385 *28 juin 20016 janv. 2004Advanced Cardiovascular Systems, Inc.Methods for polymeric coatings stents
US6676697 *17 mars 199813 janv. 2004Medinol Ltd.Stent with variable features to optimize support and method of making such stent
US6676700 *1 nov. 200113 janv. 2004Advanced Cardiovascular Systems, Inc.Stent with radiopaque core
US6679980 *13 juin 200120 janv. 2004Advanced Cardiovascular Systems, Inc.Apparatus for electropolishing a stent
US6846323 *15 mai 200325 janv. 2005Advanced Cardiovascular Systems, Inc.Intravascular stent
US20020004101 *30 août 200110 janv. 2002Schneider (Usa) Inc.Drug coating with topcoat
US20060014720 *15 sept. 200519 janv. 2006Advanced Cardiovascular Systems, Inc.Heparin prodrugs and drug delivery stents formed therefrom
Référencé par
Brevet citant Date de dépôt Date de publication Déposant Titre
US812379930 nov. 200128 févr. 2012Advanced Cardiovascular Systems, Inc.Modified implantable device surface and a method of making the same
US82631706 janv. 201011 sept. 2012Advanced Cardiovascular Systems, Inc.Methods for immobilizing anti-thrombogenic material onto a medical device or into a coating thereon
US83828155 août 200926 févr. 2013Advanced Cardiovascular Systems, Inc.TiNxCy modified surface for an implantable device and a method of producing the same
US847001930 nov. 200125 juin 2013Advanced Cardiovascular Systems, Inc.TiNxOy modified surface for an implantable device and a method of producing the same
US883455528 janv. 201316 sept. 2014Abbott Cardiovascular Systems Inc.TiNxCy modified surface for an implantable device and a method of producing the same
US886481824 juin 201321 oct. 2014Abbott Cardiovascular Systems Inc.TiNxOy Modified surface for an implantable device and a method of producing the same
US956130927 mai 20047 févr. 2017Advanced Cardiovascular Systems, Inc.Antifouling heparin coatings
US20090299463 *5 août 20093 déc. 2009Advanced Cardiovascular Systems, Inc.Modified Surface For An Implantable Device And A Method Of Producing The Same
US20100173065 *6 janv. 20108 juil. 2010Advanced Cardiovascular Systems, Inc.Methods For Immobilizing Anti-Thrombogenic Material Onto A Medical Device Or Into A Coating Thereon
Classifications
Classification aux États-Unis623/1.46, 427/2.25
Classification internationaleA61L31/10, A61L33/10, A61F2/00, A61L33/00, A61F2/82, A61F2/92
Classification coopérativeY10S623/921, A61L31/10, A61F2/07, A61F2/92, A61L33/0011, A61F2250/0067, A61F2/0077, A61F2/82, A61F2002/072, A61F2002/075, A61L2420/08
Classification européenneA61F2/07, A61F2/82, A61L33/00H2, A61L31/10